In the lab of biochemist and immunologist Christoph Rader, Ph.D., The Scripps Research Institute, Florida have engineered a new anti-cancer antibody intended to enhance cancer-fighting strategies by attracting killer T cells.
All news from Anaesthesiology
A new study suggests, for the first time in women over age 70, that working up a sweat can reduce the influence one's genes have on obesity. If you're up there in age and feel like you can coast as a couch potato, you might want to reconsider.
A total of five more patient deaths have been linked to two liquid-filled intragastric balloon systems used to treat obesity, according to an alert to healthcare providers today from the US Food and Drug Administration (FDA).
The cost of treating advanced colorectal cancer is twice as expensive in the United States as it is in Canada, even though outcomes are similar. A new study found that the overall survival was nearly identical.
According to the results of a phase III trial presented at the 2018 ASCO Annual Meeting, two simple over-the-counter medicines high dose esomeprazole and low dose aspirin when taken regularly can moderately lessen the risk of high-grade esophageal cancer.
Deaths from treatable conditions may cost the world trillions of dollars each year, according to a newly published analysis led by Harvard Medical School researchers believed to be the first to quantify the economic impact of insufficient access to high-quality medical care.
Asthma and respiratory viruses don't go well together. Weakened by the common cold or the flu, a person suffering an asthma attack often responds poorly to emergency treatment; some must be hospitalized. This is especially true for preschoolers.
The drug crizotinib has activity against a number of genetic targets relevant to non-small cell lung cancer, already earning FDA-approval against ALK- and ROS1-positive lung cancers. Now updated phase 1 clinical trial results presented at the American Association for Clinical Oncology (ASCO) Annual Meeting 2018 show a 40% response rate and 6.7-month median progression-free survival from crizotinib in highly MET-amplified non-small cell lung cancer, as well.
Anyone who gets an artificial hip or knee joint has to spend a lot of time in rehabilitation. The offers are scarce, though, and working people often cannot make the appointments due to time constraints. The result: the therapy is delayed, there are additional costs, and there is the added risk of possible health restrictions.
In the ReMove-It project, Fraunhofer and its partners have developed telemedicine-based exercise therapy that allows patients to organize their rehabilitation more flexibly. The efficacy has already been proved in a representative study, and ReMove-It is expected to be approved as a medical device by 2019.
A teenager's father is murdered in Somalia, and the boy travels to the United States seeking asylum. Another teen's father and brother are murdered by extremist groups in Afghanistan and he too makes his way to the U.S. to seek asylum. Since both are minors, federal law decrees that they must be held separately from adults under the oversight of the Office of Refugee Resettlement (ORR).
The U.S. Food and Drug Administration approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia (fever, often with other signs of infection, associated with an abnormally low number of infection-fighting white blood cells), in patients with non-myeloid (non-bone marrow) cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.